There has been no long-term use of Diovan in patients with unilateral or bilateral renal artery stenosis, but an effect similar to that seen with ACE inhibitors should be anticipated. In mice, a dose-related increase in the incidence of hepatocellular adenomas was observed at naproxen 500 doses ? 70 mg/kg/day or approximately 0.1 times the maximum recommended human dose (MRHD) on a mg/m2 basis. Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org), or emergency room immediately. Based on AUC and half-life, multiple-dose pharmacokinetic profiles of naproxen and ethinyl estradiol following administration of tablets containing 2.5 mg of naproxen acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID; N=13). ULTRAM® is not recommended for obstetrical preoperative medication or for post-delivery analgesia in nursing mothers because its safety in infants and newborns has not been studied. NOTE: Photosensitization reactions have occurred most frequently with demeclocycline, less with chlortetracycline, and very rarely with naproxen 500 and tetracycline. Body as a Whole — Frequent: chest pain, chills; Infrequent: chills and fever, face edema, intentional overdose, malaise, pelvic pain, suicide attempt; Rare: acute abdominal syndrome, hypothermia, intentional injury, neuroleptic malignant syndrome18, photosensitivity reaction. Accordingly, prothrombin time should be carefully monitored when NAPROXEN 500 therapy is initiated or stopped. Acetaminophen is recommended as the analgesic/antipyretic of choice in aspirin/NSAID-sensitive patients. If it is necessary to continue the diuretic, initiate therapy with NAPROXEN at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized. Properly discard this product when it is expired or no longer needed. NAPROXEN 500® (pantoprazole sodium) Delayed-Release Tablets are supplied as 40 mg yellow oval biconvex delayed-release tablets imprinted with NAPROXEN 500 (brown ink) on one side.